| 摘要 |
<p>A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking composition thereby inducing the lymphoma cells to undergo Fas-mediated cytotoxicity. The Fas-cross-linking composition may be an agonist anti-human Fas monoclonal antibody or fragments thereof, soluble Fas-ligand (Fas-L), and a combination thereof. In another embodiment, the lymphoma is pretreated with a composition that enhances Fas-mediated cytotoxicity induced by a Fas-cross-linking composition, followed by treatment with the Fas-cross-linking composition.</p> |
